178 results about "Bifidobacterium longum" patented technology

The invention belongs to the technical field of health-care products, and particularly relates to a fermented composition beneficial to enhancing immunity and a preparation method thereof. The fermentation composition for improving immunity is prepared by taking yeast beta-glucan, an elderberry extract, glucoraphanin, sea cucumber peptide, inulin and a traditional Chinese medicine zymolyte as fermentation raw materials, firstly inoculating bacillus coagulans and staphylococcus xylosus for aerobic fermentation, and then inoculating bifidobacterium longum for anaerobic fermentation, the aerobic fermentation stage and the anaerobic fermentation stage have a synergistic effect, so that the fermentation speed can be increased, the fermentation time can be shortened, and richer nutrient substances can be provided, and therefore, the composition has an excellent effect of enhancing the immunity; the fermentation composition is applied to preparation of capsules helpful for enhancing immunity, is helpful for enhancing human immunity, and can solve the problem that active substances in existing health-care products are difficult to effectively absorb by human bodies, so that the effect of enhancing immunity is influenced.

The invention relates to the technical field of microbiological detection and molecular biology, in particular to a specific detection primer for bifidobacterium longum subsp. Longum BBMN68 and application of the specific detection primer. The specific primer for detecting the bifidobacterium longum subsp.longum BBMN68, provided by the invention, comprises an upstream primer and a downstream primer, and nucleotide sequences are shown as SEQ ID NO.7-8. The invention also provides a kit for detecting the bifidobacterium longum subsp.longum BBMN68. The specific DNA fragment provided by the invention is a specific molecular marker of BBMN68, and the specific primer is designed aiming at the fragment sequence, so that the specific amplification of the strain can be realized, no cross reaction is caused to other related strains, the detection sensitivity is higher, and the detection requirements of samples with different concentrations can be met; the method can be used for specific detection and accurate quantification of the BBMN68 strain in yoghourt and other products, and has good practical application value.

The invention belongs to the technical field of microorganisms and fermentation engineering, and particularly relates to application of bifidobacterium longum subsp. Infantis Y46 in the aspects of enhancing cell defense and repair and regulating metabolic homeostasis of a host. The strain is isolated from infant feces. Animal experiments prove that living cell thalli of the bifidobacterium longum subsp. Infantis Y46, which are obtained by culturing an MRS liquid culture medium added with L-cysteine hydrochloride (0.05%, v / v), can significantly enhance the oxidative stress resistance of an organism and reduce the level of active oxygen in the organism compared with a control bacterium bifidobacterium longum subsp. Infantis 15697. Transcriptomics analysis shows that the bifidobacterium longum subsp. Infantis Y46 can enhance self-protection of cells and improve physiological imbalance caused by external pressure by regulating related signal channels of an organism. The action mechanism is closely related to signaling pathways related to cell defense, metabolic homeostasis and barrier functions. The invention provides a new strain resource and an application scheme for developing functional food or medicinal preparations for enhancing the health defense function of a human body.

The invention belongs to the technical field of microorganisms and fermentation engineering, and particularly relates to application of bifidobacterium longum subsp. Infantis Y46 in the anti-aging aspect. The bifidobacterium longum subsp. Infantis Y46 is obtained from excrement of infants. Animal experiments prove that living cell thalli (Y46) and thermally inactivated cell thalli (HKY46) obtained by culturing the bifidobacterium longum subsp. Infantis Y46 by using an MRS liquid culture medium containing L-cysteine hydrochloride (0.05%, v / v) can significantly reduce accumulation of lipofuscin in a host, and prolong the healthy life and life of the host. Therefore, the bifidobacterium longum subsp. Infantis Y46 is a promising probiotic and a promising metagen with an anti-aging function.

The invention belongs to the technical field of microorganisms, and particularly relates to bifidobacterium longum with high yield of nano-selenium and application of the bifidobacterium longum in production of nano-selenium, the bifidobacterium longum with high yield of nano-selenium can convert inorganic selenium salt into nano-selenium, and the content of nano-selenium enriched in freeze-dried bacterial powder is up to 24000mg / kg. The selenium-rich feed additive can be directly used for selenium dietary supplements or selenium-rich animal product production, and has potential application prospects in the fields of selenium-rich food and feed additives.

The invention discloses bifidobacterium longum B14 with efficient lactose degradation capability and low gas production characteristic and application of the bifidobacterium longum B14, and belongs to the technical field of microorganisms. The preservation number of the bifidobacterium longum B14 is GDMCC No: 67276. The bifidobacterium longum B14 strain provided by the invention can effectively decompose lactose in intestinal tracts, meanwhile, uncomfortable symptoms such as abdominal distension caused by gas production are reduced to the maximum extent, and the technical problem that in the prior art, an efficient lactose degradation strain and the low gas production characteristic are difficult to consider at the same time is successfully solved. The invention provides a core strain resource for developing probiotic products capable of relieving main symptoms of lactose intolerance and remarkably reducing side effects. The strain has a definite application prospect and a remarkable industrial value in development of health care products and medicines.

The invention belongs to the technical field of nutritious food, and particularly discloses a composition for promoting brain development and application thereof. The composition for promoting brain development provided by the invention comprises bifidobacterium longum subsp. Infantis i18 and sn-2 site docosahexaenoic acid. According to the composition provided by the invention, all the components have a synergistic effect, so that the accumulation of DHA in cerebral cortex and hippocampus can be remarkably improved, and the purpose of promoting brain development is achieved. The composition is suitable for health food, formula milk powder or fermented milk and other products for improving cognition and promoting brain development.

A Bifidobacterium longum subsp. longum dipro-017. The Bifidobacterium longum subsp. longum dipro-017 used has the ability to metabolize tryptophan to produce indole-3-lactic acid, can inhibit the pathogenic bacteria Salmonella Typhimurium, Staphylococcus aureus, and Escherichia coli, and can effectively mitigate weight loss caused by ulcerative colitis, improve a DAI score, improve colon length, mitigate the content of lipopolysaccharide (LPS) in blood, and increase the level of anti-inflammatory cytokine IL-10, as well as mitigate the content of bone metabolism indicators tartrate-resistant acid phosphatase (TRAP) and N-terminal propeptide of type I procollagen (PINP) in blood.

The invention relates to a polygonatum sibiricum probiotic compound preparation with an aging delaying effect and application thereof. The compound preparation comprises a polygonatum sibiricum extract and a probiotic composition, the bacterial strains in the probiotic composition comprise a combination of a bifidobacterium animalis subsp. Lactis BLa36 bacterial strain, a bifidobacterium longum BL21 bacterial strain, a bifidobacterium adolescentis BAC30 bacterial strain, a lactobacillus plantarum Lp90 bacterial strain, a lactobacillus casei LC89 bacterial strain, a bifidobacterium breve BBr60 bacterial strain and a pediococcus acidilactici CCFM7902 bacterial strain. After the rhizoma polygonati component and the probiotic component are combined for use, the rhizoma polygonati component and the probiotic component have potential synergistic effects in the aspects of improving the intestinal flora structure, regulating the intestinal environment, delaying senescence, reducing inflammation-related symptoms and the like. Moreover, further, various probiotic strains are compounded and combined for use, so that the capability of a related compound preparation in the aspect of delaying various symptoms of senescence can also be improved in a combined manner.

The present invention relates to the technical field of functional food products. Disclosed are a rose enzyme liquid and rose enzyme beverage for promoting emotional health, and a preparation method therefor. Sour cherry flesh, double-petaled red roses, roselle, and Perillae folium are subjected to a colloid mill, and water is added for extraction and separation to obtain a concentrate. The concentrate is fermented with Lactiplantibacillus plantarum and Bifidobacterium longum to obtain a rose enzyme liquid, and the rose enzyme liquid is compounded with a saffron extract, a Mentha spicata extract, a bamboo leaf flavonoid, etc. to obtain a rose enzyme beverage. The rose, roselle, sour cherry and Perillae folium, which are both medicinal and edible, are selected as raw materials. The raw materials are fermented by means of using specific probiotic strains to effectively release active ingredients, which are then converted into small molecular substances that are easily absorbed by the human body and relieve emotional anxiety. Moreover, functional ingredients comprising the saffron extract, the Mentha spicata extract and the bamboo leaf flavonoid are compounded to effectively relieve stress, regulate daily negative emotions, and promote physical and mental relaxation, and enhance mental well-being. The sour and sweet taste satisfies consumers' pursuit for flavor, taste and efficacy.

The invention belongs to the technical field of biology, and particularly relates to a complex microbial inoculant for promoting formation of a biological membrane, a microcapsule and application of the complex microbial inoculant. The complex microbial inoculant comprises lactobacillus mucus fermentation FMBL L24016DMX with the preservation number of CCTCC NO: M20241583 and bifidobacterium longum subsp. Longum FMBL B241770LS with the preservation number of CCTCC NO: M 20241993, the complex microbial inoculant can grow on a culture medium containing prebiotics, the biofilm formation amount is the highest when the complex microbial inoculant is co-cultured in a culture medium containing isomaltooligosacharide, the complex microbial inoculant is prepared into a single-layer microcapsule or a double-layer microcapsule, and the complex microbial inoculant can be used for preparing the probiotics. The endophytic fungus has good embedding rate and viable count, can resist gastrointestinal environment, has good heat resistance, and has wide application prospects.

The present invention discloses an anti-inflammatory Lactobacillus acidophilus composition for regulating immune responses, belonging to the fields of microbial technology and biomedicine. The composition comprises live lyophilized powders of Lactobacillus acidophilus, Lactobacillus plantarum, and Bifidobacterium longum, together with homologous postbiotic lyophilized powders of the same strains. By combining functionally complementary probiotics with their homologous postbiotics, a full-chain anti-inflammatory system is constructed, covering immune regulation, inflammation suppression, and intestinal barrier repair. The live bacteria enable long-term colonization and microecological regulation, while the postbiotics act rapidly, producing a synergistic effect. The composition is prepared solely from strain-derived fermentation products without exogenous additives, ensuring safety and purity, and provides a stable and efficient solution for inflammation relief and immune function optimization.

The invention discloses bifidobacterium longum subsp. Infantis for regulating intestinal motility and aquaporin and application of the bifidobacterium longum subsp. Infantis, and belongs to the technical field of microorganisms. According to the invention, the bifidobacterium longum subsp. Infantis CCFM1269 is screened, and the bifidobacterium longum subsp. Infantis CCFM1269 has the effects of intestinal motility and aquaporin, specifically, the defecation frequency is reduced, and the water content of excrement and the small intestine propulsion rate are reduced. The intestinal motility abnormality is relieved by reducing the levels of neurotransmitters 5-HT, SP and VIP, and the intestinal moisture absorption and secretion are regulated by improving the mRNA expression of aquaporin AQP4 and AQP8. Meanwhile, the intestinal flora is adjusted by improving the diversity of the intestinal flora, and the content of propionic acid and butyric acid in excrement is increased.

The invention provides a bifidobacterium longum and longan aril composition capable of synergistically relieving chronic fatigue, the bifidobacterium longum is named as BB36, the preservation number is CGMCC (China General Microbiological Culture Collection Center) NO.34123, and the preservation date is April 8, 2025. By improving the levels of stress hormones and neurotransmitters and reducing the serum inflammation level, the strain significantly improves the chronic fatigue symptom and improves the athletic ability; the invention further develops a bifidobacterium longum and longan aril composition capable of synergistically relieving chronic fatigue, and through compounding of probiotics and longan aril extract, it is found that the probiotics and the longan aril extract can cooperate with each other, and the composition has a synergistic effect in relieving chronic fatigue.

The application belongs to the technical field of microbial fermentation, and specifically discloses a method for producing gamma-aminobutyric acid by using Lactobacillus hilgardii and application of the method. The method comprises the following steps: (1) activating the strain; (2) seed liquid culture; (3) fermentation culture: inoculating the tertiary seed liquid into a fermentation tank containing a fermentation medium, and performing two-stage fermentation culture to obtain a fermentation liquid; and in the whole fermentation process, glucose solution or sodium glutamate solution is continuously added, and in the first-stage fermentation and the second-stage fermentation, black fungus water extraction solution and long bifidobacterium fermentation solution are continuously added, respectively; and (4) inactivation and filtration. The method can effectively promote the growth of the bacteria and optimize the metabolic state of the bacteria by adopting a two-stage fermentation control strategy and continuously adding specific feed in the main fermentation process, so that the metabolic flow is more directed to the synthesis of GABA, thereby effectively improving the yield of GABA.

The present application relates to the application of Bifidobacterium longum subsp.longum BL21 in the preparation of a preparation for improving hematopoietic dysfunction, wherein the Bifidobacterium longum subsp.longum BL21 is a Bifidobacterium longum subsp.longum BL21 strain with a preservation number of CGMCC No.10452.The present application develops a new microbial strategy for improving hematopoietic dysfunction, and uses the Bifidobacterium longum subsp.longum BL21 in the preparation of a preparation for improving hematopoietic dysfunction.It is found that the Bifidobacterium longum subsp.longum BL21 can increase the number of peripheral blood cells (red blood cells and white blood cells), the content of platelets or the content of hemoglobin, reverse the weight loss caused by hematopoietic dysfunction, and improve the serum inflammatory response and the spleen inflammatory response caused by hematopoietic dysfunction.The present application also provides a new idea for the wide application of the Bifidobacterium longum subsp.longum BL21.

The invention provides a composition. The composition is prepared from probiotics, a plant extract and acceptable auxiliary materials according to a specific content ratio. Wherein the probiotics comprise the following components: Weizmannia coagulans AUSA001, Lactobacillus plantarum AUSA002, Bifidobacterium longum subsp. Longum FL006, and the probiotics comprise the following components: the Weizmannia coagulans AUSA001, the Lactobacillus plantarum AUSA002, the Bifidobacterium longum subsp. Longum FL006, the Lactobacillus plantarum AUSA002 and the Bifidobacterium longum subsp. Longum FL006. The plant extract comprises a kudzuvine root extract, a grape seed extract and a turmeric extract. The composition has a synergistic effect, can reduce the content of human intestinal trimethylamine and serum trimethylamine oxide, and is used for prevention or adjuvant therapy of related diseases.

The application provides bifidobacterium longum MG-G763 for improving constipation, and belongs to the technical field of microorganisms. The bifidobacterium longum MG-G763 provided by the application can effectively relieve constipation by integrating multiple effects such as nerve regulation, immune regulation, barrier repair and flora regulation, and systematically restoring intestinal function homeostasis. The bifidobacterium longum MG-G763 can significantly improve the defecation particle number and defecation weight of constipated mice, shorten the time for defecating the first black stool, improve the small intestinal transport rate of the mice, effectively improve and relieve the defecation condition of the constipated mice, and significantly increase the amount of intestinal beneficial bacteria and reduce the amount of harmful bacteria, thereby promoting intestinal health.

The application discloses a Bifidobacterium longum subsp.longum strain for relieving pathological characteristics of mice with chronic kidney disease induced by adenine, and belongs to the technical fields of microorganisms and medicines.The application provides a biomarker combination related to end-stage renal disease of peritoneal dialysis, wherein the corresponding species abundance in the biomarker combination presents significant difference in matched healthy control population and peritoneal dialysis population, can effectively distinguish the end-stage renal disease population of peritoneal dialysis and the healthy population, and has high sensitivity and specificity.The application also provides a Bifidobacterium longum subsp.longum strain CCFM1375 capable of delaying the progression of renal failure, which can be used for preparing products for improving chronic kidney disease.

The application belongs to the technical field of microorganisms, and particularly discloses application of Bifidobacterium longum subsp. longum CGMCC No. 20105 in bacteriostasis. The application discloses for the first time that the Bifidobacterium longum subsp. longum strain CGMCC No. 20105 has the ability to ferment TPY or MRS to synthesize bacteriostatic substances, and the fermentation liquor has certain inhibitory effect on intestinal pathogenic bacteria, oral pathogenic bacteria, environmental pathogenic bacteria and antibiotic-resistant microorganisms. More importantly, the fermentation product does not affect the survival performance of conventional probiotics, indicating that the bacteriostatic substances synthesized by the Bifidobacterium longum subsp. longum strain CGMCC No. 20105 fermentation have certain safety, specificity and pertinence. Compared with other MRS fermentation strains, the bacteriostatic effect of the MRS fermentation liquor of the Bifidobacterium longum subsp. longum strain CGMCC No. 20105 is remarkable, and therefore has potential application value.

The invention relates to the technical field of medicines, and discloses a bifidobacterium longum strain GZBAI 01 and application thereof in degradation of benzoic acid and prevention or treatment of colorectal cancer. The strain is separated from faeces of healthy people, genomics identification is carried out, the metabolic profile of the strain is measured through metabonomics, the strain can convert benzoic acid with carcinogenic risk into protocatechuic acid with antitumor activity through unique metabolic capability, meanwhile, the function of regulatory T cells (Treg) in tumor drainage lymph nodes can be inhibited, differentiation of CD8 + T cells is promoted, and the tumor drainage lymph nodes can be inhibited. Therefore, the colorectal cancer is prevented through double ways of eliminating cancerogen and generating therapeutic agents. A colorectal cancer mouse model and a subcutaneous tumor mouse model verify that the strain can significantly reduce the number and volume of tumors, and shows a benzoic acid conversion effect superior to that of other strains in vivo and in vitro, and a new way is provided for prevention and treatment of colorectal cancer.

The application discloses application of Bifidobacterium longum exopolysaccharide or a co-incubation extractive solution of the Bifidobacterium longum exopolysaccharide and probiotics in improving inflammation. The application finds that the Bifidobacterium longum exopolysaccharide and the co-incubation extractive solution of the Bifidobacterium longum exopolysaccharide and Lactobacillus acidophilus can inhibit LPS-induced TLR4 / NfkB (P65) signal path activation, inhibit the polarization of macrophages from M0 to M1, thereby inhibiting inflammatory reactions, and the inhibiting effect of the co-incubation extractive solution of the Bifidobacterium longum exopolysaccharide and Lactobacillus acidophilus is more obvious. Therefore, the Bifidobacterium longum exopolysaccharide and the co-incubation extractive solution of the Bifidobacterium longum exopolysaccharide and Lactobacillus acidophilus can be used for preparing drugs for inhibiting inflammatory reactions, and are helpful to the treatment of immune and chronic inflammatory diseases and the development of related drugs.

Bifidobacterium longum strains and cell wall fractions isolated from Bifidobacterium longum strains are useful in the prophylaxis or treatment of an infection in a subject caused by a coronavirus such as SARS-CoV-2. They are also useful in the prophylaxis of a secondary bacterial infection associated with an infection in a subject caused by a coronavirus, especially a subject who is susceptible to respiratory infections.

Use of a composition comprising bacteria for odor reduction in the treatment of symptoms of tissue necrosis, wound secretions or putrid wounds or a disease selected from the group consisting of ozena, hyperhidrosis, osmidrosis, chronic urinary tract infections, chlamydial infections and halitosis; wherein the composition comprises the bacteria Lactobacillus acidophilus TYCA15, Lactobacillus salivarius, Bifidobacterium animalis, Bifidobacterium bifidum and Bifidobacterium longum in the ratio 1:1:1:1:1; and the composition totals 10 9 bacteria per gram of the composition.

The invention relates to the technical field of compositions, and particularly discloses a composition for bidirectionally regulating diarrhea and constipation and promoting Akk proliferation and application. The composition for bidirectionally regulating diarrhea and constipation and promoting Akk proliferation, provided by the invention, comprises bifidobacterium longum subsp. Infantis i18 and casei paracasei N1115. In the composition provided by the invention, all the components have a synergistic effect, so that diarrhea and constipation can be safely, effectively and bidirectionally regulated and improved, the intestinal microecological steady state can be further maintained by promoting Akk proliferation, and the composition has a wide application prospect.

This invention belongs to the field of cosmetic technology, and particularly relates to a fermented milk containing Artemisia annua with oil-controlling, acne-reducing, and anti-inflammatory effects, its preparation method, and application. The preparation method includes the following steps: S1, inoculating Tremella fuciformis seed liquid into Artemisia annua culture medium for aerobic fermentation to obtain Tremella fuciformis fermentation broth; S2, separating the Tremella fuciformis fermentation broth into bacterial cells to obtain Tremella fuciformis fermentation product filtrate; S3, inoculating Bifidobacterium longum seed liquid into the Tremella fuciformis fermentation product filtrate for anaerobic fermentation to obtain Bifidobacterium longum fermentation broth; S4, separating the Bifidobacterium longum fermentation broth into bacterial cells to obtain Bifidobacterium longum fermentation product filtrate and its bacterial cells; S5, disrupting the bacterial cells to obtain their lysate, then adding the lysate to the Bifidobacterium longum fermentation product filtrate, mixing, and obtaining Artemisia annua fermented milk. The fermented milk has significant multiple effects, including soothing sensitivity, acne reduction, oil control, anti-inflammation, antibacterial properties, and moisturizing.

A Bifidobacterium longum subsp longum produced by a method of growing the Bifidobacterium longum subsp longum in a culture medium, the culture medium containing a fructose disaccharide, FOS or combination thereof. A method for treatment or prevention of inflammatory bowel disease, celiac disease, non-celiac gluten sensitivity, gluten ataxia, dermatitis herpetiformis or wheat allergy in an individual, the method including administering a combination of (i) Bifidobacterium longum subsp longum and (ii) a fructose disaccharide, FOS or a combination thereof to the individual.

Use of a fructose disaccharide or fructooligosaccharide, for increasing protein production in Bifidobacterium longum subsp longum.

The invention relates to the technical field of probiotics, in particular to an application of a probiotic (Bifidobacterium longum) in allergic asthma (preventing, relieving or treating allergic asthma). The invention relates to an application of probiotics in allergic asthma, in particular to an application of the probiotics in inhibiting a PI3K / AKT / NF-kappa B signal channel. According to the probiotics disclosed by the invention, activation of a PI3K / AKT / NF-kappa B signal channel is specifically inhibited, immune imbalance is regulated and controlled from the source, and Th2 type immune response is effectively inhibited. Specifically, the total IgE level in serum and the expression of Th2 type cytokines such as IL-4, IL-5 and IL-13 are remarkably reduced, the inflammatory response of the airway mainly caused by eosinophilic granulocyte infiltration is relieved, and the airway high reactivity and airway remodeling are effectively improved. The invention provides a novel intervention strategy which is clear in mechanism, high in safety and capable of treating both symptoms and root causes according to the intestine-lung axis theory, and has a wide application prospect in the aspect of treating allergic asthma.

The invention belongs to the technical field of microorganisms, food science and medicine, and particularly relates to bifidobacterium longum subsp.infantis SZBLI1052 and application thereof. The invention discloses that the obvious synergistic anti-inflammatory effect exists between the specific strain B. longa subsp. Infantis SZBLI1052 and the arachidonic acid (ARA) for the first time, and the specific strain B. longa subsp. Infantis SZBLI1052 has the obvious synergistic anti-inflammatory effect on the arachidonic acid (ARA) and the arachidonic acid (ARA). Compared with the single use of SZBLI1052 or ARA, the combined use of SZBLI1052 and ARA shows a synergistic effect, so that the LPS-induced inflammatory response can be more effectively inhibited, and the protection effect on the intestinal barrier is enhanced. The invention also finds that the strain SZBLI1052 can specifically and obviously consume ARA, and can efficiently metabolize and convert ARA into a key metabolite lipoxin B4 (LXB4) with anti-inflammatory activity. The composition of the SZBLI1052 and the ARA is applied to the infant formula milk, and the synergistic anti-inflammatory effect of the composition is verified. The discovery of the invention lays a solid foundation for developing a new generation of functional infant formula food with synergistic anti-inflammatory characteristics, and has important application potential and industrialization value in the aspect of realizing precise immune nutrition intervention of newborns.